Expression constructs
A human PTPRG-WT expression construct (coding sequence from reference sequence NM_002841.3) was obtained from Vector Builder (Cyagen Biosciences Inc., Santa Clara, CA, USA). The encoded sequence corresponds to the 1445 aa long splice version of PTPRG (Ensembl ENST00000474889.5). A human PTPN6-WT expression construct was originally obtained from Dr. Axel Ullrich (Max-Planck Institute of Biochemistry, Martinsried, Germany). Both coding sequences were subcloned to pMSCV-IRES-mCherry (Addgene # 52114), and mutated to PTPRG-C1060S and PTPN6-C453S respectively using the QuikChange XL Site-Directed Mutagenesis Kit (Agilent Technologies, Waldbronn, Germany; Cat. #200517) according to the instructions of the manufacturer. The PTPRC expression construct was obtained from Dr. Reiner Lammers (University Hospital Tübingen, Germany). It encodes PTPRC isoform 2 (NP_563578.2) [1] . The PTPRC insert was subcloned into a lentiviral expression vector pLV-mCherry/Bsd, containing a mCherry/blasticidin resistance cassette (Vector Builder, Cyagen Biosciences Inc., Santa Clara, CA, USA). Cells transduced with viral particles produced with respective empty vectors were used as controls. All coding sequences and mutations were confirmed by DNA sequencing. Target cells were infected with freshly produced viral particles using a standard protocol, selected with 7.5 µg/µl blasticidin (Life Technologies, R21001) (only PTPRC-vector and corresponding control), and sorted for equally high expression of mCherry. Cell sets with empty vector, expression vector, and mutated vector (if applicable) were generated and processed in parallel.
shRNA mediated knockdown of PTPN6
Stable KCL-22 cell pools with knockdown of PTPN6 were obtained by lentiviral transduction of KCL-22 cells with viral particles made from pLKO.1 (Sigma-Aldrich) constructs harbouring either nontargeting control (Cat # SHC002; insert: CCGGCA ACAAGATGAAGAGCACCAACTCGAGTTGGTGCT CTTCATCTTGTTGTTTTT), or shPTPN6-A (Cat # TRCN0000006885; insert: CCGGCCCAGTTCATTG AAACCACTACTCGAGTAGTGGTTTCAATGAACTG GGTTTTT), or shPTPN6-B (Cat # TRCN0000006886; insert: CCGGGCATGACACAACCGAATACAACTC GAGTTGTATTCGGTTGTGTCATGCTTTTT) and subsequent selection with 2 µg/ml puromycine (SigmaAldrich, P8833).
CRISPR/Cas 9 mediated knockout of PTPN6 and PTPRC
Stable PTPN6 and PTPRC knockout cells were generated by infecting the parental cells with viral particles freshly made from lentiCRISPR v2 plasmid (Addgene #52961) containing target specific gRNA (GAAGA ACTTGCACCAGCGTC for PTPN6 clones A and B; TTACCACATGTTGGCTTAGA or TTAATATTAGATG TGCCACC for PTPRC clones A and B respectively). Cells infected with viral particles made from empty lentiCRISPR v2 plasmid were used as controls. Infected cells were selected using 2 µg/ml puromycin and single cell clones were established by limited dilution and analyzed for absence of the target protein by immunoblotting. Two independent knockout clones were selected for further analysis.
Immunoblotting
Cells were washed with ice-cold PBS and lysed on ice in RIPA lysis buffer (1 % NP40, 1 mM EDTA, 50 mM Tris pH 7.4, 150 mM NaCl, 0.25 % sodium deoxycholate) containing PhosSTOP phosphatase inhibitor cocktail (Roche, Mannheim, Germany; Cat. # 04906845001) and cOmplete protease inhibitor cocktail (Roche, Mannheim, Germany; Cat. # 04693132001) www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
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diluted in lysis buffer according to the instructions of the manufacturer. The extracts were sonicated, and the cleared lysates were subjected to SDS-PAGE and transferred to nitrocellulose membranes using tank blot. Membranes were first incubated with the phospho-antibodies as applicable, and subsequently stripped for detection of respective total proteins. Antibodies were obtained from the following companies: Cell Signaling Technology (New England Biolabs GmbH, Heidelberg, Germany): pBCR-ABL1 (pABL #2861), BCR-ABL1 (ABL #2862), pSFK (#6943), pERK 1/2 (#9106), ERK 1/2 (#9107); SANTA CRUZ BIOTHECHNOLOGY (Heidelberg, Germany): PTPN6 (sc-287), PTPRC (sc-25590), p27 (sc-1641), Bcl-2 (sc-7382), cSRC (sc-18), Lyn (sc-7274), STAT5 (sc-835); Sigma-Aldrich: actin (A5441); BIOZOL: vinculin (BZL03106); BD Biosciences (Heidelberg, Germany): pSTAT5 (BD611964). The PTPRG antibody was generated in one of our laboratories as described before [2] . Quantification of blots was done using Fujifilm Multi Gauge software. Intensity of phosphorylation signals was divided by intensity of respective blot for the total proteins. To normalize levels of p27 and Bcl-2, specific signals were divided by the signal for actin. For each individual experiment, the respective signals are reported relative to EV or control cell signals. The mean of these relative phosphorylation signals of n = 3 independent experiments is reported +/-standard deviation (SD).
